Method of producing human pluripotent stem cells by somatic cell nuclear transfer

Case ID:
1838
Web Published:
8/5/2020
Description:

Summary

This is a method for producing patient-matched histocompatible pluripotent stem cells (PSC’s) by somatic cell nuclear transfer (SCNT).

Technology Overview

Pluripotent stem cells only naturally exist in early human embryos.  The current methods produce experimental pluripotent stem cells (PSC’s) using the patient’s own skin cells as a starting point. Human PSC’s derived by SCNT are histocompatible to a patient who provide skin cells, while conventional embryonic stem cells (ESC’s) are isogenic. Furthermore, PSC’s derived by SCNT have the same advantages of embryo derived ESC’s since mitochondria and mitochondria DNA in skin cells are replaced by the oocyte’s material. This is a distinct advantage as currently available histocompatible induced pluripotent stem cells (iPS cells) contain aged or diseased mitochondria and mitochondria DNA from the patient’s cells. The OHSU method combines benefits, but excludes disadvantages of the other two existing pluripotent stem cell types.

Publication

Tachibana et al., “Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer.” Cell 153(2013): 1228-1238. Link

Licensing Opportunity

This technology is available for licensing and/or co-development.

Patent Information:
For Information, Contact:
Trina Voss
Senior Technology Development Manager
Oregon Health & Science University
503-494-8200
vosst@ohsu.edu
Inventors:
Shoukhrat Mitalipov
Masahito Tachibana
Keywords:
Research Tools
Therapeutics
Therapeutics - Reproductive
© 2023. All Rights Reserved. Powered by Inteum